LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Начало・Списък с акции・Design Therapeutics Inc

Design Therapeutics Inc

Затворен

14.36 -0.55

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.02

Максимум

14.41

Ключови измерители
By Trading Economics
Приходи	-1.6M -18M
EPS	-0.29
Служители	54
EBITDA	-1.5M -20M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+18.3% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	175M 975M
Предишно отваряне	14.91
Предишно затваряне	14.36

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

3.26 / 3.63 Подкрепа & съпротива

Design Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.05.2026 г., 23:53 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15.05.2026 г., 22:47 ч. UTC

Горещи акции

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15.05.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15.05.2026 г., 22:00 ч. UTC

Значими двигатели на пазара

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15.05.2026 г., 18:09 ч. UTC

Значими двигатели на пазара

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17.05.2026 г., 23:50 ч. UTC

Пазарно говорене

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

17.05.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17.05.2026 г., 23:36 ч. UTC

Пазарно говорене

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17.05.2026 г., 23:07 ч. UTC

Придобивния, сливания и поглъщания

UOB: Transactions Part of Group's Capital Reallocation Strategy

17.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

UOB: Share Sale Agreements Entered With Singland Properties

17.05.2026 г., 23:05 ч. UTC

Придобивния, сливания и поглъщания

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Fund Stake Acquisition via Internal Resources

17.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Acquire Stake for $389 Million

17.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16.05.2026 г., 16:27 ч. UTC

Придобивния, сливания и поглъщания

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16.05.2026 г., 15:26 ч. UTC

Придобивния, сливания и поглъщания

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15.05.2026 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15.05.2026 г., 21:16 ч. UTC

Пазарно говорене

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 20:19 ч. UTC

Горещи акции

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15.05.2026 г., 19:41 ч. UTC

Придобивния, сливания и поглъщания

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15.05.2026 г., 19:35 ч. UTC

Пазарно говорене

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15.05.2026 г., 18:35 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Design Therapeutics Inc Прогноза

Ценова цел

By TipRanks

18.3% нагоре

12-месечна прогноза

Среден 17 USD 18.3%

Висок 21 USD

Нисък 14 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Design Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Design Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.26 / 3.63Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.